Allergan picks up AZ’ Crohn’s drug in $1.52bn deal
AstraZeneca’s biologics research and development arm MedImmune has signed over global rights to its experimental Crohn’s disease drug MEDI2070 to Allergan, in a deal potentially worth $1.52 billion.
Read More
